23 March 2026 in Nature Communications
Personalized vaccines demonstrate remarkable potential in leveraging tumor-specific adaptive immunity for cancer therapy. Nevertheless, current platforms face persistent challenges, including premature systemic clearance and imprecise antigen-presenting cell targeting, culminating in transient and inefficient antitumor immunity. Furthermore, the technical complexity, extended timelines, and prohibitive costs required for tumor-specific neoantigen identification continue to impede the clinical translation of personalized cancer vaccines. Here, we report a tumor-derived extracellular vesicle-based scaffold vaccine that elicits robust and durable antitumor immunity for personalized cancer immunotherapy. Following subcutaneous administration, the in situ-formed hydrogel vaccine serves as a sustained reservoir for tumor-derived extracellular vesicle antigens and adjuvants while recruiting antigen-presenting dendritic cells to accumulate within the scaffold. Upon exposure to this antigen-rich depot, immature dendritic cells undergo efficient activation, with subsequently matured dendritic cells migrating to draining lymph nodes, where they induce potent and persistent tumor-specific CD8+ T-cell responses that suppress tumor progression across multiple murine models. Specifically, when using tumor-derived extracellular vesicles isolated from surgically excised tumor tissues, the patient-tailored vaccines demonstrate remarkable efficacy in preventing postoperative recurrence. Our findings validate the robust and durable therapeutic efficacy of this vaccine platform, highlighting its potential as a customizable strategy for personalized cancer immunotherapy.
4 September 2026 in Science Advances
The success of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies has not been translated to solid tumors, primarily due to inadequate T cell infiltration and an immunosuppressive tumor microenvironment that drives T cell exhaustion. To address these challenges, we developed a tailored immunomodulatory drug-drug conjugate-based hydrogelator for the localized delivery of CAR-T cells targeting solid tumors. This hydrogel forms an in situ scaffold that serves as a sustained-release reservoir, enabling continuous co-delivery of CAR-T cells along with immunomodulatory agents—NLG919 (an IDO-1 inhibitor) and D PPA-1 (a PD-L1 antagonistic peptide)—to synergistically remodel the immunosuppressive tumor microenvironment and promote robust tumor recognition and elimination. Notably, this approach significantly enhances CAR-T cell infiltration and persistence, stimulates a potent endogenous tumor-specific immune response, while also establishing long-lasting immunological memory. In murine models of aggressive melanoma, metastatic breast cancer, and postoperative glioma, a single local administration of the hydrogel resulted in significant suppression of tumor growth, rechallenge, metastasis and recurrence. By integrating localized CAR-T cell delivery with in situ immune reprogramming, this system represents a versatile and clinically translatable platform that substantially improves the efficacy of CAR-T cell therapy against solid tumors.